Your browser doesn't support javascript.
Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic.
Müllerová, Hana; Medin, Jennie; Arnold, Matthew; Gomes da Silva, Hugo; Kumar, Supriya; Nord, Magnus; Hubbard, Richard; de Lusignan, Simon.
  • Müllerová H; Medical Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK hana.muellerova@astrazeneca.com.
  • Medin J; Medical Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
  • Arnold M; Real World Evidence Data and Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Gomes da Silva H; Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Kumar S; Real World Evidence Data and Analytics, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • Nord M; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden.
  • Hubbard R; Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
  • de Lusignan S; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
BMJ Open ; 13(1): e063645, 2023 01 13.
Article in English | MEDLINE | ID: covidwho-2193770
ABSTRACT

OBJECTIVES:

During COVID-19 vaccination programmes, new safety signals have emerged for vaccines, including extremely rare cases of thrombosis with thrombocytopaenia syndrome (TTS). Background event rates before and during the pandemic are essential for contextualisation of such infrequent events. In the literature, most studies do not report an overall TTS event rate. Rather, background rates are mainly reported for subtypes of thrombotic/thromboembolic diagnoses included in the TTS clinical definition mostly by anatomical location, with reported rates for TTS subtypes varying widely. The objective of this study was to report prepandemic TTS background event rates in the general population.

METHODS:

Prepandemic background TTS rates were generated via secondary data analysis using a cohort design in the IBM Truven MarketScan (now Merative MarketScan) US health insurance claims database, from 1 January 2019 to 31 December 2019. Two algorithms were applied thrombocytopaenia occurring±7 days (algorithm 1) or occurring 1 day prior to ≤14 days after the thrombotic/thromboembolic event (algorithm 2).

RESULTS:

The study population derived from the MarketScan database analysis included approximately 9.8 million adults (aged ≥18 years; mean age 45 years, 52% females). Using this study population, prepandemic background TTS incidence was estimated as 9.8-11.1 per 100 000 person-years. Event rates were higher in males and increased with age. Similar patterns were observed with both algorithms.

CONCLUSIONS:

This study presents an estimate of aggregate prepandemic background TTS event rates including by type of thrombosis/thromboembolism and age group. The background event rates are dependent on the precision of capturing underlying TTS events in variable data sources, and the ability of electronic health records or insurance claims databases to reflect the TTS clinical definition. Differences between reported event rates demonstrate that estimating background event rates for rare, unprecedented safety events is methodologically challenging.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombocytopenia / Thromboembolism / Thrombosis / COVID-19 Vaccines / COVID-19 / Anemia Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: English Journal: BMJ Open Year: 2023 Document Type: Article Affiliation country: Bmjopen-2022-063645

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombocytopenia / Thromboembolism / Thrombosis / COVID-19 Vaccines / COVID-19 / Anemia Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: English Journal: BMJ Open Year: 2023 Document Type: Article Affiliation country: Bmjopen-2022-063645